The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Safety of Double‐Dose Transdermal Scopolamine
Abstract
Study Objective. To evaluate the safety of double‐dose transdermal scopolamine patch therapy. Design. Randomized, crossover, double‐blind study. Setting. Motion sickness clinic in Haifa, Israel. Participants. Twenty male sailors aged 18–21 years whose seasickness symptoms improved only slightly or not at all with a single transdermal scopolamine patch. Intervention. Subjects received either two transdermal scopolamine patches or one scopolamine patch plus a placebo patch for 24 hours (first session). After at least 1 week from the end of the first session, they received the other treatment for 24 hours (second session). Measurements and Main Results. Plasma scopolamine concentrations, physiologic (heart rate and blood pressure), visual, and cognitive function parameters, and adverse effects were assessed before the first session (baseline) and after each 24‐hour session. Visual function was tested again 24 hours after patch removal. Subjects also completed an adverse‐effects questionnaire immediately after and 24 hours after patch removal for both treatment sessions. A significant difference was found in mean plasma scopolamine concentrations between the single‐dose and double‐dose treatments (81 vs 127 pg/ml [therapeutic level 100 pg/ml], p<0.01). No significant differences were found in heart rate, blood pressure, cognitive function, or visual function measurements. Mild blurred vision was the only adverse effect for which there was a significant difference between the single‐dose and double‐dose treatments; however, this adverse effect was judged to be not clinically significant. Conclusion. Double‐dose transdermal scopolamine may improve treatment in patients who fail to respond to a single patch by increasing the plasma scopolamine concentration, without aggravating systemic, visual, or cognitive adverse effects. Thus we recommend that a double dose can be administered safely to these patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Drugs such as promethazine and scopolamine provide protective benefit (Bar et al. 2009; Davis et al. 1993; Graybiel and Lackner 1987; Gordon et al. 2001; Klocker et al. 2001; Nachum et al. 2001, 2006; Simmons et al. 2010).”
From Motion sickness: more than nausea and vomiting (2014) · cites this paper as Bar et al. 2009
Citations
Cites
Scopolamine (hyoscine) for preventing and treating motion sickness
Spinks, A., & Wasiak, J. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002851.pub4 · Cited by 152
Clissold, S. P., & Heel, R. C. (1985) · Drugs · doi:10.2165/00003495-198529030-00001 · Cited by 138
Transdermal Scopolamine for Prevention of Motion Sickness
Nachum, Z., Shupak, A., & Gordon, C. R. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645060-00001 · Cited by 120
Transdermal scopolamine in the prevention of motion sickness at sea
Price, N. M., Schmitt, L. G., McGuire, J., Shaw, J. E., & Trobough, G. (1981) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1981.57 · Cited by 103
Parrott, A. C. (1989) · PubMed · Cited by 66
Scopolamine Bioavailability in Combined Oral and Transdermal Delivery
Nachum, Z., Shahal, B., Shupak, A., Spitzer, O., Gonen, A., Beiran, I., Lavon, H., Eynan, M., Dachir, S., & Levy, A. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29671-3 · Cited by 53
Prevention of experimental motion sickness by scopolamine absorbed through the skin.
Graybiel, A., Knepton, J. C., & Shaw, J. E. (1976) · PubMed · Cited by 49
Synovial Chondromatosis of the Temporomandibular Joint
Fee, W. E., Windhorst, P., Wiggins, R., & Pang, L. (1979) · Otolaryngology · doi:10.1177/019459987908700606 · Cited by 47
Transdermal drug administration--a nuisance becomes an opportunity.
Shaw, J. E., & Urquhart, J. (1981) · BMJ · doi:10.1136/bmj.283.6296.875 · Cited by 45
Scopolamine (hyoscine) for preventing and treating motion sickness
Spinks, A. B., Wasiak, J., Bernath, V. F., & Villanueva, E. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002851.pub3 · Cited by 43
Research works printed but not linked: 9
- Reason JT, 1975, Motion sickness
- Price N, 1979, Transdermal delivery of scopolamine for prevention of motion‐induced nausea in rough seas, Clin Ther, 2, 258
- Doweck I, 1995, Rate of absorption of scopolamine after application of Scopoderm‐TTS [abstract], Aviat Space Environ Med, 66, 467
- Shaw JE, 1977, Transdermally administered scopolamine for prevention of motion sickness in a vertical oscillator [abstract], Clin Pharmacol Ther, 21, 117
- Ensing K, 1986, Pharmacokinetics of free and glucuronidated scopolamine following transdermal delivery of scopolamine in children [abstract], Acta Pharmacol Toxicol Copenh, 59, 81
- Shaw JE, 1981, Drug absorption, 186
- Shaw JE, 1975, Use of percutaneous absorption for systemic administration of drugs, Pharm J, 215, 325
- Fee WE, 1979, The effect of transdermal therapeutic system‐scopolamine in controlling acute vertigo [abstract], Otolaryngol Head Neck Surg, 87, 240
- Gonen A, 1998, Comparison of performance under the influence of three antimotion sickness drugs [abstract], Aviat Space Environ Med, 69, 209
Cited by
Motion sickness: more than nausea and vomiting
Lackner, J. R. (2014) · Experimental Brain Research · doi:10.1007/s00221-014-4008-8 · Cited by 314
“Drugs such as promethazine and scopolamine provide protective benefit (Bar et al. 2009; Davis et al. 1993; G raybiel and Lackner 1987; Gordon et al. 2001; Klocker et al. 2001; Nachum et al. 2001, 2006; Simmons et al. 2010).”
BackgroundScopolamine (hyoscine) for preventing and treating motion sickness
Spinks, A., & Wasiak, J. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002851.pub4 · Cited by 152
Leung, A. K. C., & Hon, K. E. (2019) · Drugs in Context · doi:10.7573/dic.2019-9-4 · Cited by 129
Murdin, L. J., Golding, J. B., & Bronstein, A. M. (2011) · BMJ · doi:10.1136/bmj.d7430 · Cited by 85
Cholinergic Blockade Frees Fear Extinction from Its Contextual Dependency
Zelikowsky, M., Hast, T. A., Bennett, R. Z., Merjanian, M., Nocera, N. A., Ponnusamy, R., & Fanselow, M. S. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.08.006 · Cited by 74
Metadata
- Authors
- Bar, R., Gil, A., & Tal, D.
- Affiliations
- Israel Defense Forces Medical Corps (IL)
- Corresponding author
- Bar, Ronen
- Venue
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Publisher
- Wiley
- Published
- 2009-09
- Volume
- 29
- Issue
- 9
- Pages
- 1082-1088
- ISSN
- 0277-0008 (ISSN-L)
- 1875-9114
- OpenAlex
- W2127469418
- Cited by
- 13
- References
- 23
- Citations by year
- 2023: 1 · 2019: 2 · 2014: 3 · 2012: 1
- FWCI
- 2.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Nausea and vomiting management
- Life Sciences › Neuroscience › Neurology › Vestibular and auditory disorders
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Keywords
- transdermal scopolamine, seasickness, motion sickness, adverse effects, blurred vision, heart rate, blood pressure, cognitive function, visual function, sailors
- MeSH terms
- Administration, Cutaneous, Adolescent, Double-Blind Method, Drug Administration Schedule, Humans, Israel, Male, Military Personnel, Motion Sickness, Surveys and Questionnaires, Scopolamine, Cross-Over Studies, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
